Where Mirum Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Mirum Pharmaceuticals (NASDAQ:MIRM) in the last quarter. The average price target is $72.0, implying an upside from the current price of $25.309. This represents a 4.95% decrease from the previous average price target of $75.75.
August 21, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given bullish ratings for Mirum Pharmaceuticals, with an average price target of $72.0, indicating potential upside.
The bullish ratings from analysts indicate a positive outlook for Mirum Pharmaceuticals. The average price target of $72.0 is significantly higher than the current price, suggesting potential upside. However, the decrease from the previous average price target could indicate some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100